• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antibiotics >The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia
【24h】

The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia

机译：抗念珠菌生物膜的抗真菌药在导管相关念珠菌血症中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Catheter-related bloodstream infection (C-RBSI) is one of the most frequent nosocomial infections. It is associated with high rates of morbidity and mortality. Candida spp. is the third most common cause of C-RBSI after coagulase-negative staphylococci and Staphylococcus aureus and is responsible for approximately 8% of episodes. The main cause of catheter-related candidemia is the ability of some Candida strains—mainly C. albicans and C. parapsilosis—to produce biofilms. Many in vitro and in vivo models have been designed to assess the activity of antifungal drugs against Candida biofilms. Echinocandins have proven to be the most active antifungal drugs. Potential options in situations where the catheter cannot be removed include the combination of systemic and lock antifungal therapy. However, well-designed and -executed clinical trials must be performed before firm recommendations can be issued.
机译：导管相关的血流感染（C-RBSI）是最常见的医院感染之一。它与高发病率和死亡率相关。念珠菌属是C-RBSI的第三大最常见病因，仅次于凝固酶阴性葡萄球菌和金黄色葡萄球菌，约占8％的发作原因。导管相关念珠菌血症的主要原因是某些念珠菌菌株（主要是白色念珠菌和副念珠菌）产生生物膜的能力。已经设计了许多体外和体内模型来评估抗真菌药物对念珠菌生物膜的活性。棘球and素已被证明是最活跃的抗真菌药。在无法移除导管的情况下，可能的选择包括全身和锁定抗真菌治疗的组合。但是，必须发布经过精心设计和执行的临床试验，然后才能发布明确的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号